← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin
cloricromen
B01AC02
Forms & Strengths
- Oral capsules 100 mg
- Injectable solution 10 mg/mL
Adult Dosing
- 100 mg orally two to three times daily
- Intravenous infusion 10-20 mg daily in acute settings
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Prevention of thromboembolic disorders
- Adjunct therapy in peripheral vascular disease
- Reduction of platelet aggregation in high-risk cardiovascular patients
Mechanism of Action
- Acts as a platelet aggregation inhibitor
- Enhances prostacyclin production and inhibits thromboxane A2 synthesis
- Exerts vasoprotective and anti-inflammatory effects on the vascular endothelium
Contraindications
- Known hypersensitivity to cloricromen or its excipients
- Active pathological bleeding such as peptic ulcer or intracranial hemorrhage
- Severe hepatic impairment
Adverse Reactions
- Mild to moderate gastrointestinal distress (dyspepsia, nausea)
- Increased risk of bleeding and bruising
- Headache and dizziness
- Transient flushing
Drug Interactions
- Increased bleeding risk when combined with anticoagulants (warfarin, heparin)
- Enhanced antiplatelet effects with concurrent NSAIDs, aspirin, or P2Y12 inhibitors
- Potentiation of hypotensive effects with antihypertensive agents
Curated Content: Needs Vetting Before Put to Clinical Use